---
title: "Trulicity (dulaglutide) in type 2 diabetes: Specific populations questions"
description: "Specific populations questions on Trulicity (dulaglutide) in type 2 diabetes, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Pediatric use. Questions: At what age can children use Trulicity? How much does Trulicity lower A1C in children 10 and older? What are the side effects of Trulicity in children? 3 questions quoted from 1 source."
canonical: "https://www.evicenter.com/medical-information/trulicity--type-2-diabetes/specific-populations"
published: "2026-11-13T03:43:41-05:00"
modified: "2026-11-14T16:49:54-05:00"
---

# Trulicity (dulaglutide) in type 2 diabetes: Specific populations questions

Manufacturer: Eli Lilly and Company  
Prescribing information: [Trulicity](https://uspl.lilly.com/trulicity/trulicity.html#pi)

Specific populations questions that apply to every indication of Trulicity are on [Trulicity (dulaglutide), all indications: Specific populations](https://www.evicenter.com/medical-information/trulicity/specific-populations).

## Specific populations

<a id="trulicity-children-age"></a>

### At what age can children use Trulicity?

Applies to: Glycemic control as an adjunct to diet and exercise in pediatric patients 10 years of age and older with type 2 diabetes mellitus

> “The safety and effectiveness of TRULICITY as an adjunct to diet and exercise to improve glycemic control in pediatric patients 10 years of age and older with type 2 diabetes mellitus have been established. Use of TRULICITY for this indication is supported by a 26-week, multicenter, randomized, double-blind, parallel arm, placebo-controlled trial in 154 pediatric patients 10 years of age and older with type 2 diabetes mellitus [see Clinical Studies (14.6)].”

Source: [TRULICITY: Prescribing information, captured 2026-11-13](https://uspl.lilly.com/trulicity/trulicity.html#pi:~:text=The%20safety%20and%20effectiveness%20of,mellitus%20%5Bsee%20Clinical%20Studies%20%2814.6%29%5D.)

> “The safety and effectiveness of TRULICITY have not been established in pediatric patients less than 10 years of age.”

Source: [TRULICITY: Prescribing information, captured 2026-11-13](https://uspl.lilly.com/trulicity/trulicity.html#pi:~:text=The%20safety%20and%20effectiveness%20of%20TRULICITY%20have,than%2010%20years%20of%20age.)

## Pediatric use

<a id="trulicity-peds-a1c"></a>

### How much does Trulicity lower A1C in children 10 and older?

Applies to: Glycemic control as an adjunct to diet and exercise in pediatric patients 10 years of age and older with type 2 diabetes mellitus

> “In this 26-week randomized, double-blind, placebo-controlled, parallel-arm, multicenter trial with an open-label extension for an additional 26 weeks,154 pediatric patients 10 years of age and older with type 2 diabetes mellitus, who had inadequate glycemic control despite diet and exercise, were randomized to subcutaneous TRULICITY once weekly (0.75 mg and 1.5 mg) or subcutaneous placebo once weekly in combination with or without metformin and/or basal insulin treatment (NCT02963766).”

Source: [TRULICITY: Prescribing information, captured 2026-11-13](https://uspl.lilly.com/trulicity/trulicity.html#pi:~:text=In%20this%2026%2Dweek%20randomized%2C%20double%2Dblind%2C,and%2For%20basal%20insulin%20treatment%20%28NCT02963766%29.)

> “In this trial, once weekly TRULICITY (0.75 mg and 1.5 mg, pooled) (with or without metformin and/or basal insulin) was superior to placebo (p<0.001) in the change from baseline at Week 26 in HbA1c in pediatric patients 10 years of age and older with type 2 diabetes mellitus (see Table 15).”

Source: [TRULICITY: Prescribing information, captured 2026-11-13](https://uspl.lilly.com/trulicity/trulicity.html#pi:~:text=In%20this%20trial%2C%20once%20weekly,diabetes%20mellitus%20%28see%20Table%2015%29.)

> “Table 15: Glycemic Results at Week 26 in Pediatric Patients 10 Years of Age and Older with Type 2 Diabetes Mellitus with Inadequate Glycemic Control Despite Diet and Exercise (With or Without Metformin and/or Basal Insulin)
>
> Abbreviations: HbA1c = hemoglobin A1c.
>
>
>
>
> a Combined results for TRULICITY 0.75 mg and 1.5 mg. The comparison of the two dosages together and individually with placebo was prespecified with overall type I error controlled.
>
>
>
>
> b The change from baseline and difference from placebo were analyzed using analysis of covariance with effects for treatment, the baseline value as a covariate, and stratification factors which were HbA1c at screening (< 8% vs >= 8%), insulin use at baseline (yes/no), metformin use at baseline (yes/no).
>
>
>
>
> c For HbA1c and Fasting Blood Glucose, multiple imputation was performed for missing data guided by washout method. At Week 26 primary efficacy (HbA1c) was missing for 8%, 6%, and 10% of patients on placebo, TRULICITY 0.75 mg and TRULICITY 1.5 mg respectively.
>
>
>
>
> d For percentage of patients HbA1c < 7%, missing data was imputed as not achieving the target.
>
>
> 	Placebo	TRULICITY 0.75 mg once weekly	TRULICITY 1.5 mg once weekly	TRULICITY once weekly
> Pooleda
> Intent-to-Treat Population (N)	51	51	52	103
> HbA1c (%) (Mean)c
> Baseline
> Change from baseline at Week 26b
> Difference from placebo (95% CI)b	8.1
> 0.6
> -	7.9
> -0.6
> -1.2 (-1.8, -0.6)	8.2
> -0.9
> -1.5 (-2.1, -0.9)	8.0
> -0.8
> -1.4 (-1.9, -0.8)
> Percentage of Patients with HbA1c <7.0% at Week 26d	14%	55%	48%	52%
> Fasting Blood Glucose (mg/dL) (Mean)c
> Baseline
> Change from baseline at Week 26b
> Difference from placebo (95% CI)b	159
> 17.1
> -	149
> -12.8
> -29.9 (-50.7, -9.1)	163
> -24.9
> -42.0 (-63.0, -20.9)	156
> -18.9
> -35.9 (-54.2, -17.6)”

Source: [TRULICITY: Prescribing information, captured 2026-11-13](https://uspl.lilly.com/trulicity/trulicity.html#pi:~:text=Table%2015%3A%20Glycemic%20Results%20at,%2D35.9%20%28%2D54.2%2C%20%2D17.6%29)

Note: Table 15 columns are placebo, TRULICITY 0.75 mg, TRULICITY 1.5 mg, and the pooled TRULICITY group. In the HbA1c and fasting blood glucose rows the label lists, for each column in turn, the baseline value, the change from baseline at Week 26, and the difference from placebo.

<a id="trulicity-peds-side-effects"></a>

### What are the side effects of Trulicity in children?

Applies to: Glycemic control as an adjunct to diet and exercise in pediatric patients 10 years of age and older with type 2 diabetes mellitus

> “TRULICITY was administered to 150 pediatric patients 10 years of age and older with type 2 diabetes mellitus for a mean duration of 41.3 weeks [see Clinical Studies (14.6)]. The mean age was 14.5 years and 71% of patients were female. Overall, 55% were White, 15% were Black or African American, 12% were Asian, 10% were American Indian or Alaska Native, 5% were other races, and 3% had unknown race. Additionally, 55% were Hispanic or Latino, 42% were not Hispanic or Latino, and 3% had unknown ethnicity. At baseline, the mean duration of type 2 diabetes mellitus was 2 years, mean HbA1c was 8.1%, mean weight was 90.5 kg and mean BMI was 34.1 kg/m2.”

Source: [TRULICITY: Prescribing information, captured 2026-11-13](https://uspl.lilly.com/trulicity/trulicity.html#pi:~:text=TRULICITY%20was%20administered%20to%20150,mean%20BMI%20was%2034.1%20kg%2Fm2.)

> “The safety profile in pediatric patients treated with TRULICITY 0.75 mg and 1.5 mg subcutaneously once-weekly was consistent with that described above for adult patients with type 2 diabetes mellitus with the exception of injection site reactions. In pediatric patients, the incidence of injection site reactions was 3.9% (2 patients) in the TRULICITY 0.75 mg group, 3.8% (2 patients) in the TRULICITY 1.5 mg group, and 2.0% (1 patient) in the placebo group.”

Source: [TRULICITY: Prescribing information, captured 2026-11-13](https://uspl.lilly.com/trulicity/trulicity.html#pi:~:text=The%20safety%20profile%20in%20pediatric,patient%29%20in%20the%20placebo%20group.)

> “During the 26-week controlled period of the glycemic control trial in pediatric patients 10 years of age or older with type 2 diabetes mellitus [see Clinical Studies (14.6)], 4/101 (4%) of TRULICITY-treated pediatric patients developed ADA. Of the 4 pediatric patients that developed ADA, 1 patient (1% of the overall population) developed dulaglutide-neutralizing antibodies and 3 patients (3% of the overall population) developed antibodies against native GLP-1. During the 52-week postbaseline period of the same trial (through safety follow-up), 6/103 (6%) of TRULICITY-treated patients developed ADA. Of the 6 patients that developed ADA, 1 patient (1% of the overall population) developed dulaglutide-neutralizing antibodies and 4 patients (4% of the overall population) developed antibodies against native GLP-1. Because of the low occurrence of ADA, the effect of these antibodies on the pharmacokinetics, pharmacodynamics, safety, and/or effectiveness of TRULICITY is unknown in pediatric patients.”

Source: [TRULICITY: Prescribing information, captured 2026-11-13](https://uspl.lilly.com/trulicity/trulicity.html#pi:~:text=During%20the%2026%2Dweek%20controlled%20period,is%20unknown%20in%20pediatric%20patients.)

## Related pages
- [Medical information: Trulicity (dulaglutide): Type 2 diabetes](https://www.evicenter.com/medical-information/trulicity--type-2-diabetes)
- [Indication](https://www.evicenter.com/medical-information/trulicity--type-2-diabetes/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/trulicity--type-2-diabetes/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/trulicity--type-2-diabetes/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/trulicity--type-2-diabetes/safety)
- [Dosing and administration](https://www.evicenter.com/medical-information/trulicity--type-2-diabetes/dosing-and-administration)
- [Access and coverage](https://www.evicenter.com/medical-information/trulicity--type-2-diabetes/access-and-coverage)
- [Guidelines](https://www.evicenter.com/medical-information/trulicity--type-2-diabetes/guidelines)
